NEUROPROTEOMICS AND SIGNALING OF BRAIN DISORDERS
Department: Neuroscience

{slider Research subject|opened|grey}

The team is developing a neuroproteomic project that has two main objectives: i) to characterize the signaling networks associated with several serotonin receptors and their role in various neurological and psychiatric disorders (mood disorders, schizophrenia, Alzheimer's disease, neuropathic pain), ii) to identify biomarkers of neurological disorders and determine their impact on these diseases. It is based on a multidisciplinary strategy based on (phospho)proteomic approaches associated with biochemical, electrophysiological and behavioral studies.

Our efforts focus on three serotonin receptors, the 5-HT2A, 5-HT4 and 5-HT6 receptors.

The 5-HT2A receptor is a major target of antipsychotics and psychedelic hallucinogens such as LSD. This receptor interacts with another antipsychotic target, the metabotropic glutamate mGlu2 receptor, to form heteromers that play a key role in the therapeutic response to antipsychotics. We are investigating the signaling mechanisms of 5-HT2A/mGlu2 heteromers and their impact on synaptic transmission and plasticity.

The 5-HT4 receptor, which exerts pro-cognitive effects and promotes the non-amyloidogenic cleavage of the amyloid precursor protein (APP) and thus prevents the accumulation of amyloid peptide in senile plaques, is a potential target to slow down the progression of Alzheimer's disease and alleviate associated cognitive symptoms. We are characterizing the signaling mechanisms involved in the non-amyloidogenic cleavage of APP and study the impact of the receptor on the evolution of the disease in preclinical models. In line with the role of the 5-HT4 receptor in the maturation of the enteric nervous system by the gut microbiota, the team recently initiated a project to characterize the impact of the microbiota on the development of Alzheimer's disease.

The 5-HT6 receptor plays a key role in neuronal development and is a promising target for treating the cognitive symptoms of Alzheimer's disease and schizophrenia. We are looking for novel receptor-mediated signaling pathways involved in neuronal differentiation, synaptogenesis and cognition, which are potential targets for the treatment of cognitive impairment in dementia or psychoses. In collaboration with chemist teams, we participate in the development of new compounds targeting 5-HT4 or 5-HT6 receptors (or both receptors) and the characterization of their therapeutic potential.

Our work on biomarkers is currently focused on the search for prognostic biomarkers of multiple sclerosis and the study of the impact of a panel of biomarkers identified in the cerebrospinal fluid by quantitative proteomics on the progression of the disease.

 

img.marin.200

{slider Team|grey}

Team leader

Philippe Marin
DRCE, CNRS


  IGF Sud 221

  04 34 35 92 42


Researchers

Carine Becamel
MCF, UM


  IGF Sud 224

  04 34 35 92 15


Éric Thouvenot
PU-PH1, UM


  IGF Sud 026

  04 34 35 92 06


Franck Vandermoere
DR2, CNRS


  IGF Sud 221

  04 34 35 92 13


Joel Bockaert
PU, UM


  IGF Sud 215

  04 34 35 92 42


Julien Villeneuve
CRCN, CNRS


  IGF Sud 219

  04 34 35 92 23


Marie-Laure Parmentier
DR2, Inserm


  IGF Sud 219

  04 34 35 92 23


Philippe Coubes
PU-PH1, UM


  IGF Sud 224

  04 34 35 92 15


Séverine Chaumont-Dubel
MCF, UM


  IGF Sud 029

  04 34 35 92 17


Sylvie Claeysen
CRHC, Inserm


  IGF Sud 224

  04 34 35 92 15


Technicians and engineers

Magali Lançon
TCS, UM


  IGF Sud 204

  04 34 35 92 16


Sonya Galant
IECN, CNRS


  IGF Sud 221

  04 34 35 92 13


Postdoctoral researchers and doctoral students

Aurore Filaquier
Doctorant(e), UM


  IGF Sud 221

  04 34 35 92 13


Clemence Quittet
Doctorant(e), UM


  IGF Sud 029

  04 34 35 92 17


Eloise Neel
Doctorant(e), CNRS


  IGF Sud 221

  04 34 35 92 23


Lucy Kundura
Chercheur CDD, Inserm


  IGF Sud 224

  04 34 35 92 15


Marylou Grasso
Doctorant(e), CHU


  IGF Sud 215

  04 34 35 92 42


Thomas Curel
Doctorant(e), Inserm


  IGF Sud 224

  04 34 35 92 15


Tomas del Olmo
Chercheur CDD, Inserm


  IGF Sud 224

  04 34 35 92 16


Fixed term contract technicians and engineers

Candice Disdier
IR CDD, Inserm


  IGF Sud 221

  04 34 35 92 13


Emma Estrems Velazquez
IE CDD, UM


  IGF Sud 224

  04 34 35 92 15


Linda-Nora Mekki
IE CDD, Inserm


  IGF Sud 224

  04 34 35 92 15


Mehdi Sekssaoui
IE CDD, CNRS


  IGF Sud 001

  04 34 35 92 15


Morgane Denus
IE CDD, CNRS


  IGF Sud 221

  04 34 35 92 23


Ophélie Bento
IE CDD, CNRS


  IGF Sud 026

  04 34 35 92 06


William Fargues
IE CDD, CNRS


  IGF Sud 225

  04 34 35 93 46


Trainees

Louane Chambouleyron
Stagiaire, CNRS


  IGF Sud 224

  04 34 35 92 15



{slider Major publications|grey}

  • Conejero I, Collombier L, Lopez-Castroman J, Mura T, Alonso S, Olié E, Boudousq V, Boulet F, Arquizan C, Boulet C, Wacongne A, Heitz C, Castelli C, Mouchabac S, Courtet P, Abbar M, Thouvenot E. Association between brain metabolism and clinical course of motor functional neurological disorders. Brain. 2022 Sep 14;145(9):3264-3273. doi: 10.1093/brain/awac146. PMID: 35445242.

  • Fumagalli A, Heuninck J, Pizzoccaro A, Moutin E, Koenen J, Séveno M, Durroux T, Junier MP, Schlecht-Louf G, Bachelerie F, Schütz D, Stumm R, Smit MJ, Guérineau NC, Chaumont-Dubel S, Marin P. The atypical chemokine receptor 3 interacts with Connexin 43 inhibiting astrocytic gap junctional intercellular communication. Nat Commun. 2020 Sep 25;11(1):4855. doi: 10.1038/s41467-020-18634-y. PMID: 32978390; PMCID: PMC7519114.

  • Berthoux C, Hamieh AM, Rogliardo A, Doucet EL, Coudert C, Ango F, Grychowska K, Chaumont-Dubel S, Zajdel P, Maldonado R, Bockaert J, Marin P, Bécamel C. Early 5-HT6 receptor blockade prevents symptom onset in a model of adolescent cannabis abuse. EMBO Mol Med. 2020 May 8;12(5):e10605. doi: 10.15252/emmm.201910605. Epub 2020 Apr 24. Erratum in: EMBO Mol Med. 2022 Sep 7;14(9):e16481. PMID: 32329240; PMCID: PMC7207164.

  • Pujol CN, Dupuy V, Séveno M, Runtz L, Bockaert J, Marin P, Chaumont-Dubel S. Dynamic interactions of the 5-HT6 receptor with protein partners control dendritic tree morphogenesis. Sci Signal. 2020 Feb 11;13(618):eaax9520. doi: 10.1126/scisignal.aax9520. PMID: 32047117.

  • Murat S, Bigot M, Chapron J, König GM, Kostenis E, Battaglia G, Nicoletti F, Bourinet E, Bockaert J, Marin P, Vandermoere F. 5-HT(2A) receptor-dependent phosphorylation of mGlu(2) receptor at Serine 843 promotes mGlu(2) receptor-operated G(i/o) signaling. Mol Psychiatry. 2018 Jun 1.
 

Events

Mon Tue Wed Thu Fri Sat Sun
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31